Page last updated: 2024-11-09

4-maleimido-2,2,6,6-tetramethylpiperidinooxyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-maleimido-TEMPO : A member of the class of piperidines that is TEMPO carrying a maleimido group at position 4. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2724304
CHEBI ID180675
MeSH IDM0068252

Synonyms (24)

Synonym
4-maleimido-2,2,6,6-tetramethylpiperidinyloxyl
mal-6
4-maleimido-2,2,6,6-tetramethylpiperidine-1-oxyl
CHEBI:180675
4-maleimido-tempo, for esr-spectroscopy
tempo-maleimide
4-maleimido-tempo
15178-63-9
2,2,6,6-tetramethylpiperdin-n-1-oxymaleimide
oxytetramethyl piperidinyl maleimide
4-maleimido-2,2,6,6-tetramethylpiperidinooxyl
4-n-maleimido-2,2,6,6-tetramethylpiperidine nitroxide
4-n-maleimido-2,2,6,6-tetramethylpiperidine-1-oxyl
2,2,6,6-tetramethyl-4-maleimidopiperidine-1-oxyl
4-maleimido-2,2,6,6-tetramethylpiperidin1-1-yloxy
1-piperidinyloxy, 4-(2,5-dihydro-2,5-dioxo-1h-pyrrol-1-yl)-2,2,6,6-tetramethyl-
nem-tempo
a 25335-9
n-(1-oxyl-2,2,6,6-tetramethyl-4-piperidinyl)maleimide
FT-0629076
AKOS015916573
4-(2,5-dihydro-2,5-dioxo-1h-pyrrol-1-yl)-2,2,6,6-tetramethyl-1-piperidinyloxy
DTXSID30934344
[4-(2,5-dioxo-2,5-dihydro-1h-pyrrol-1-yl)-2,2,6,6-tetramethylpiperidin-1-yl]oxidanyl
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
radical scavengerA role played by a substance that can react readily with, and thereby eliminate, radicals.
spin labelA role played by a stable paramagnetic group that is attached to a part of a molecular entity whose microscopic environment is of interest and may be revealed by the electron spin resonance (ESR) spectroscopy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
aminoxylsRadicals derived from hydroxylamines by removal of the hydrogen atom from the hydroxy group. The synonymous terms nitroxyl radicals and nitroxides erroneously suggest the presence of a nitro group.
piperidines
maleimidesCompounds containing a cyclic dicarboximide skeleton in which the two carboacyl groups on nitrogen together with the nitrogen itself form a 1H-pyrrole-2,5-dione structure.
dicarboximideAn imide in which the two acyl substituents on nitrogen are carboacyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (86)

TimeframeStudies, This Drug (%)All Drugs %
pre-199045 (52.33)18.7374
1990's31 (36.05)18.2507
2000's8 (9.30)29.6817
2010's2 (2.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.53 (24.57)
Research Supply Index4.48 (2.92)
Research Growth Index4.00 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other87 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]